Shanghai Microport Medbot (group) Co., Ltd. Class H · HKEX:2252
Shanghai Microport Medbot (group) Co., Ltd. Class H — H1 2024 Earnings Presentation
27 slides from Shanghai Microport Medbot (group) Co., Ltd. Class H's earnings presentation, Sep 4, 2024
Slide 1: 2024 Interim Results Presentation
2024 Interim Results Presentation August 2024
Slide 2: Disclaimer
Disclaimer This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of Shanghai MicroPort MedBot (Group) Co., Ltd., and no part of it shall form the
Slide 3: Agenda
AGENDA 1H24 Business Highlights Product Pipeline Update Financial Review In Closing Appendix 3
Slide 4: 1H24 Business Highlights
1H24 Business Highlights Significant Improvement in Cost Robust Revenue Growth Optimization and Operation Efficiency Revenue +108.5%YOY 48.6% YOY decrease of net loss 49.7% YOY decrease of net free cash outflow No.1 among Domestic Players New Globalization Milestone Toumai ® commercial Obtained CE m
Slide 5: Revenue ramped up on domestic and overseas markets
Business Highlights Revenue Ramped up on Solid Domestic Market and Ambitious Overseas Penetration U.S Domestic market | Revenue 65%YOY Asia ex-China 2% 9% Toumai® R-ONE® Africa - 7 units of new commercial - Achieved 2 units of 7% installation in 1H24 commercialized installation following the - Overa
Slide 6: Accelerating Global Market Penetration across Five Continents
Business Highlights Gaining Tractions from Accelerating Global Market Penetration across Five Continents Well recognized product portfolio with regulatory Toumai® achieved commercialization SkyWalkerTM continued its robust sales growth approvals from mainstream markets breakthroughs SkyWalkerTM sale
Slide 7: Leading Edge and Clinical Competency through Large-scale Surgeries
Business Highlights Demonstration of Leading Edge and Clinical Competency through Large-scale surgeries Dedicated Market Cultivation Comprehensive Coverage Accelerating Clinical surgeries For Complicated Disease Toumai® Toumai® Toumai® Toumai® ~40 No.1 • Multiple hospitals achieved ~200 First of its
Slide 8: Improved Operational Effectiveness on Cost-optimization Strategies
Business Highlights Improved Operational Effectiveness on Stringent Cost-optimization Strategies Adjusted Net Loss Optimizing Free Cash Outflow Narrowed Operational Efficiency Decreased (RMB million) (RMB million) (RMB million) 11.5% R&D S&M Admin 15.9% 42.2% 82.3% 982.4 58.0% 1,158.2 91.7% 1,110.3
Slide 9: Established the Largest Remote Surgery Network in the Globe
Business Highlights Established the Largest Remote Surgery Network in the Globe Xinjiang Orlando Beijing 12,500+ km 12,950+ km 5,000 km Shanghai Shanghai Dubai Sanya Remote surgery breakthroughs achieved： Toumai® achieved the world's 1st cross-border 5G remote simulated surgery Initiated patient enr
Slide 10: Agenda
AGENDA 1H24 Business Highlights Product Pipeline Update Financial Review In Closing Appendix 10
Slide 11: Comprehensive product offering covering major surgical specialties
Product Pipeline Update Comprehensive product offering covering all 5 major and fast-growing surgical specialties Medical Device Surgical Product Clinical Trial/ Specialty Product Indicated Application Classification Design Development Design Validation Clinical Evaluation Registration Application T
Slide 12: Flagship product – Toumai Laparoscopic Surgical Robot
Product Pipeline Update Flagship product– Toumai® Laparoscopic Surgical Robot Multiple generations of Domestic commercialization on track Toumai® clinical progress • Maintained leading position, #1 market share among domestic brands with ramped up wining bids and commercial installation: Completed t
Slide 13: Flagship product – SkyWalker Orthopedic Surgical Robot
Product Pipeline Update Flagship product – SkyWalkerTM Orthopedic Surgical Robot The 1st domestic surgical robot to expand into global market Apr 2022 Jul 2022 Apr 2023 Jul 2023 Apr 2024 Sep 2023 NMPA FDA Dec 2022 NMPA ANVISA TGA CDSCO Approval Clearance CE Marking Approval Approval Approval Approva
Slide 14: Flagship product – DFVision 3D Electronic Laparoscope
Product Pipeline Update Flagship product – DFVision® 3D Electronic Laparoscope Underlying technology to Steady commercialization – Obtained NMPA approval for contimuously optimize the high-end pioneer among domestic brands fluorescence imaging function vision platform for surgical robots Stereo visu
Slide 15: Natural Orifice Surgical Robot
Product Pipeline Update Natural Orifice Surgical Robot Trans-bronchial Surgical Robot Robot-assisted natural orifice surgery Product Surgery application Natural orifice surgical robots refer to robots that deliver surgical instruments to the target anatomy through natural pathways of the human bod
Slide 16: R-ONE Vascular Interventional Robot System
Product Pipeline Update R-ONE® Vascular Interventional Robot System Designed to operate with precision and NMPA approval perform specific movements CE mark Facilitate and enhance the interventional procedures performed on the patient Registration Approval Strong Commercialization Unique Synergy & Le
Slide 17: Mona Lisa Robotic Transperineal Prostate Biopsy System
Product Pipeline Update Mona Lisa Robotic Transperineal Prostate Biopsy System NMPA Approval Real-time ultrasound images displayed on the monitor FDA Approval during the biopsy procedure CE Marking TGA Approval The surgeon manually inserts the needle into the prostate to collect the biopsy cores HAS
Slide 18: Strong industrial operation capabilities for surgical robots
Product Pipeline Update Strong industrial operation capabilities for surgical robots 1,314 Multilayered supply chain system applications In-house designed components (459 granted) Scalable production of Toumai®, SkyWalkerTM and consumables 379 overseas applications Annual capacity over 100 units of
Slide 19: Agenda
AGENDA 1H24 Business Highlights Product Pipeline Update Financial Review In Closing Appendix 19
Slide 20: Consolidated Financial Performance
Financial Review Consolidated Financial Performance REVENUE TOTAL NET LOSS FREE CASH FLOW Total revenue reached 99.2m with 108% growth. Core Total net loss turned to decrease greatly with the strategy The success of costs reduction, operation efficiency and product Toumai® remained the leading posit
Slide 21: Operating Expenses
Financial Review Operating Expenses R&D COST S&M EXPENSES ADMINISTRATIVE EXPENSES (RMB million) (RMB million) (RMB million) 51% 7% 47% 98% 27% 336.4 19% 311.7 61% 126.9 164.1 92.2 77.6 64.2 65.1 30.1 22A 1H 23A 1H 24A 1H 22A 1H 23A 1H 24A 1H 22A 1H 23A 1H 24A 1H R&D 164.1m, 47% decline YoY S&M 92.2m
Slide 22: Agenda
AGENDA 1H24 Business Highlights Product Pipeline Update Financial Review In Closing Appendix 22
Slide 23: In Closing
In Closing We delivered record revenue and robust momentum to drive continuous growth We enjoy large, cross-border market opportunities Our comprehensive product pipeline enables technology integration, stimulates sales synergy, and provides integrated diagnostic and treatment solutions We are posit
Slide 24: Agenda
AGENDA 1H24 Business Highlights Product Pipeline Update Financial Review In Closing Appendix 24
Slide 25: Appendix I - Consolidated Balance Sheet
Appendix I - Consolidated Balance Sheet Unit: RMB'000 30 Jun 2024 31 Dec 2023 Var. Unit: RMB'000 30 Jun 2024 31 Dec 2023 Var. Non-current assets CAPITAL AND RESERVES Share capital 958,594 958,594 0% Property, plant and equipment 351,103 367,017 -4% Reserves (683,690) (439,114) 56% Intangible assets
Slide 26: Appendix II - Consolidated P&L
Appendix II - Consolidated P&L Unit: RMB'000 30 Jun 2024 30 Jun 2023 Var. Revenue 99,237 47,603 108% Cost of sales (52,224) (25,535) 105% Gross profit 47,013 22,068 113% Other net income 5,298 (23,214) -123% Selling and marketing expenses (92,223) (126,907) -27% Administrative expenses (30,072) (77,
Slide 27: Thank You
: q) MEUBOT. - PROUAN ESA: % THANK YOU BaaTae Ea) &
Shanghai MicroPort MedBot (Group) — H1 2024 Earnings Presentation on 6ix